• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Prometheus Biosciences Inc.

    6/16/23 9:10:55 AM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RXDX alert in real time by email
    S-8 POS 1 d466665ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on June 16, 2023

    Registration No. 333-254252

    Registration No. 333-270099

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO

    Form S-8 Registration No. 333-254252

    Form S-8 Registration No. 333-270099

    UNDER THE SECURITIES ACT OF 1933

     

     

    PROMETHEUS BIOSCIENCES, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   81-4282653

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    3050 Science Park Road

    San Diego, California 92121

    (858) 422-4300

    (Address of Principal Executive Offices) (Zip Code)

    PROMETHEUS BIOSCIENCES, INC. 2017 EQUITY INCENTIVE PLAN

    PROMETHEUS BIOSCIENCES, INC. 2021 INCENTIVE AWARD PLAN

    PROMETHEUS BIOSCIENCES, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN

    (Full title of the plans)

    Kelly E.W. Grez

    Secretary

    Prometheus Biosciences, Inc.

    3050 Science Park Road

    San Diego, California 92121

    (858) 422-4300

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

    Copies to:

    Scott A. Barshay

    Laura C. Turano

    Paul, Weiss, Rifkind, Wharton & Garrison LLP

    1285 Avenue of the Americas

    New York, NY 10019

    (212) 373-3000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

     

    ☒

      

    Accelerated filer

     

    ☐

    Non-accelerated filer

     

    ☐

      

    Smaller reporting company

     

    ☐

        

    Emerging growth company

     

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    DEREGISTRATION OF SECURITIES

    These Post-Effective Amendments (these “Post-Effective Amendments”) relate to the following Registration Statements on Form S-8 (each, a “Registration Statement,” and collectively, the “Registration Statements”), filed with the Securities and Exchange Commission (the “SEC”) by Prometheus Biosciences, Inc., a Delaware corporation (the “Registrant”):

     

      •  

    Registration Statement No. 333-254252, filed with the SEC on March 15, 2021, pertaining to the registration of 7,547,000 shares of the common stock of the Registrant, $0.0001 par value per share (the “Common Stock”), reserved for issuance under the Prometheus Biosciences, Inc. 2021 Incentive Award Plan (the “2021 Plan”), 53,000 shares of Common Stock subject to outstanding options granted under the 2021 Plan, 4,978,932 shares of Common Stock subject to outstanding options granted under the Prometheus Biosciences, Inc. 2017 Equity Incentive Plan and 1,160,000 shares of Common Stock reserved for issuance under the Prometheus Biosciences, Inc. 2021 Employee Stock Purchase Plan (the “ESPP”); and

     

      •  

    Registration Statement No. 333-270099, filed with the SEC on February 28, 2023, pertaining to the registration of an additional 5,390,313 shares of Common Stock reserved for issuance under the 2021 Plan and 1,208,062 shares of Common Stock reserved for issuance under the ESPP.

    On June 16, 2023, pursuant to the terms of an Agreement and Plan of Merger (the “Merger Agreement”), dated as of April 15, 2023, among Merck & Co., Inc., a New Jersey corporation (“Parent”), Splash Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”) and the Registrant, Merger Sub merged with and into the Registrant, with the Registrant surviving the merger as a wholly owned subsidiary of Parent (the “Merger”).

    As a result of the Merger and the other transactions contemplated by the Merger Agreement, the Registrant has terminated any and all offerings of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unissued at the termination of the offerings, by filing these Post-Effective Amendments, the Registrant hereby removes from registration all securities registered but unsold under such Registration Statements, if any, as of the date hereof, and the Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on June 16, 2023.

     

    PROMETHEUS BIOSCIENCES, INC.

    By:

     

    /s/ Kelly E.W. Grez

     

    Name: Kelly E.W. Grez

     

    Title: Secretary

    No other person is required to sign these Post-Effective Amendments to the Registration Statements on Form S-8 in reliance on Rule 478 of the Securities Act of 1933, as amended.

    Get the next $RXDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RXDX

    DatePrice TargetRatingAnalyst
    5/10/2023$160.00 → $200.00Buy → Hold
    Jefferies
    7/20/2022$51.00Buy
    Goldman
    6/10/2022$53.00Overweight
    Piper Sandler
    3/10/2022$50.00 → $52.00Outperform
    Credit Suisse
    3/10/2022$42.00 → $53.00Overweight
    Wells Fargo
    3/10/2022$47.00 → $55.00Outperform
    SVB Leerink
    2/11/2022$62.00Buy
    BTIG
    12/13/2021$46.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $RXDX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Prometheus Biosciences Inc.

      15-12G - Prometheus Biosciences, Inc. (0001718852) (Filer)

      6/27/23 3:06:42 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Prometheus Biosciences Inc.

      25-NSE - Prometheus Biosciences, Inc. (0001718852) (Subject)

      6/16/23 9:13:06 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Prometheus Biosciences Inc.

      S-8 POS - Prometheus Biosciences, Inc. (0001718852) (Filer)

      6/16/23 9:12:56 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Mckenna Mark C.

      4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)

      6/16/23 4:00:25 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Stenhouse Mark

      4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)

      6/16/23 4:00:32 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Hendrix Martin

      4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)

      6/16/23 4:00:40 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Prometheus Biosciences Inc. (Amendment)

      SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)

      3/8/23 5:02:07 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Prometheus Biosciences Inc. (Amendment)

      SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)

      2/14/23 4:27:18 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Prometheus Biosciences Inc. (Amendment)

      SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)

      2/14/23 3:01:42 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Prometheus Biosciences downgraded by Jefferies with a new price target

      Jefferies downgraded Prometheus Biosciences from Buy to Hold and set a new price target of $200.00 from $160.00 previously

      5/10/23 6:31:59 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Prometheus Biosciences with a new price target

      Goldman initiated coverage of Prometheus Biosciences with a rating of Buy and set a new price target of $51.00

      7/20/22 7:36:43 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Prometheus Biosciences with a new price target

      Piper Sandler initiated coverage of Prometheus Biosciences with a rating of Overweight and set a new price target of $53.00

      6/10/22 7:19:39 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $RXDX
    Financials

    Live finance-specific insights

    See more
    • Cellino Appoints Chris Gibson to Board of Directors

      Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024933617/en/Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion) Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genente

      10/24/24 8:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck Completes Acquisition of Prometheus Biosciences, Inc.

      Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn's disease and other autoimmune conditions Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. ("Prometheus") (NASDAQ:RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. "The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This transaction is anoth

      6/16/23 4:04:00 PM ET
      $MRK
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

      SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today reported financial results for the quarter ended March 31, 2023. Prometheus to be Acquired by Merck On April 15, 2023, Merck and Prometheus Biosciences entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. The transaction is expected to close in the th

      5/9/23 4:00:00 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb

      – ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p<0.0001) – – ARTEMIS-UC Cohort 1 met all ranked secondary endpoints – – APOLLO-CD trial showed 26.0% endoscopic response and 49.1% clinical remission rates (p=0.002 and p<0.001, respectively, compared to prespecified historical placebo rates) – – PRA023 demonstrated favorable safety and tolerability results across both studies with no safety signal identified – – ARTEMIS-UC Cohort 1 interim analysis suggests a trend towards increased PRA023 response in CDx+ patients over all comers – – PRA023 showed a significant impact on multiple m

      12/7/22 7:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

      Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity Discussion of Phase 1 results and rationale around SSc-ILD as new PRA023 indication to be presented in conference call scheduled today at 8:00 AM EST SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today reported positive topline results fro

      12/7/21 7:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Cellino Appoints Chris Gibson to Board of Directors

      Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024933617/en/Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion) Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genente

      10/24/24 8:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress

      - Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn's disease (CD) - - Phase 1a trial results of PRA023 in normal healthy volunteers expected in fourth quarter 2021 - - Strong cash position of $304 million as of June 30, 2021 - SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bo

      8/11/21 4:01:00 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psychedelic Science Leader Eleusis Announces Four New Board Appointments, Further Strengthening Leadership

      Eleusis, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced the appointment of four highly experienced business leaders to its board of directors. The new directors' deep expertise building high-growth, high-impact life science companies complements Eleusis's world-class leadership team. The appointees include: David Socks, former CEO of Phathom Pharmaceuticals, joining as Chair of the board Robert Hershberg, M.D., Ph.D., former CBO and CSO of Celgene John Tucker, CEO of SC Pharmaceuticals Esther van den Boom, Managing Partner at van den Boom & Associates "We are delighted to welcome these four exceptional d

      7/12/21 8:00:00 AM ET
      $RXDX
      $PASG
      $PHAT
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)